Literature DB >> 23420162

Hereditary angioedema: quality of life in Brazilian patients.

Maria Abadia Consuelo M S Gomide1, Eliana Toledo, Solange Oliveira Rodrigues Valle, Regis A Campos, Alfeu T França, Nieves Prior Gomez, Heitor Franco Andrade, Teresa Caballero, Anete S Grumach.   

Abstract

OBJECTIVE: Hereditary angioedema is a serious medical condition caused by a rare autosomal dominant genetic disorder and it is associated with deficient production or dysfunction of the C1 esterase inhibitor. In most cases, affected patients experience unexpected and recurrent crises of subcutaneous, gastrointestinal and laryngeal edema. The unpredictability, intensity and other factors associated with the disease impact the quality of life of hereditary angioedema patients. We evaluated the quality of life in Brazilian hereditary angioedema patients.
METHODS: Patients older than 15 years with any severity of hereditary angioedema and laboratory confirmation of C1 inhibitor deficiency were included. Two questionnaires were used: a clinical questionnaire and the SF-36 (a generic questionnaire). This protocol was approved by the Ethics Committee of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo.
RESULTS: The SF-36 showed that 90.4% (mean) of all the patients had a score below 70 and 9.6% had scores equal to or higher than 70. The scores of the eight dimensions ranged from 51.03 to 75.95; vitality and social aspects were more affected than other arenas. The internal consistency of the evaluation was demonstrated by a Cronbach's alpha value above 0.7 in seven of the eight domains.
CONCLUSIONS: In this study, Brazilian patients demonstrated an impaired quality of life, as measured by the SF-36. The most affected domains were those related to vitality and social characteristics. The generic SF-36 questionnaire was relevant to the evaluation of quality of life; however, there is a need for more specific instruments for better evaluation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23420162      PMCID: PMC3552471          DOI: 10.6061/clinics/2013(01)oa13

Source DB:  PubMed          Journal:  Clinics (Sao Paulo)        ISSN: 1807-5932            Impact factor:   2.365


INTRODUCTION

Hereditary angioedema (HAE) is a serious medical condition caused by a rare autosomal dominant genetic disorder that is characterized by deficient production or dysfunction of the C1 esterase inhibitor. The C1 inhibitor acts as a regulatory protein in the complement, contact, coagulation and fibrinolytic systems (1). The prevalence of HAE is estimated to be between 1:10,000 and 1:50,000 (2). Patients affected by HAE experience unexpected and recurrent “attacks” of bradykinin-mediated edema. Edema may occur in any part of the body but is most commonly observed in the face, extremities, genitals, gastrointestinal system and upper airways. Edema affecting the skin is typically painless but may cause disfigurement or difficulty driving or operating machinery. Gastrointestinal edema is very painful and can lead to unnecessary laparotomy, while upper airway edema can be life threatening due to swelling of the tongue and larynx (3). Some patients are able to identify triggering factors, although in certain cases, no factors can be found. The most common triggering factors are emotional stress, local trauma, medical or dental procedures, infection, menses and oral contraceptives (4). These attacks are unpredictable, intense and vary in terms of the site of edema. There is a potential risk of dying due to asphyxiation. The efficacy of long-term prophylactic treatment is inconsistent and it can cause side effects. All these factors decrease the quality of life of this patient population. However, few publications have described the quality of life in patients with hereditary angioedema and no specific questionnaire is currently available. The aim of the study was to evaluate the quality of life in Brazilian patients with angioedema.

METHODS

Ethical Aspects: The study protocol was approved by the Ethics Committee of the Clinics Hospital of the Faculty of Medicine of the University of São Paulo. All patients signed the informed consent form before any study procedures took place. Patient Population: Patients older than 15 years with any severity of HAE and laboratory confirmation of C1 inhibitor deficiency were included. Data Collection: Two questionnaires were used: a clinical questionnaire and the SF-36. The SF-36, a generic tool, was previously culturally adapted and validated in Brazil (5). The clinical questionnaire consisted of personal questions and information about the disease; patients were asked about their history of angioedema attacks in the previous six months, treatment, side effects of medication, influence on their social life, whether they had missed days of work or school due to attacks, visits to emergency rooms and psychological disturbances due to angioedema. A severity score was calculated according to the data considered by Agostoni et al. (3): adverse events from long-term therapy, the frequency of attacks, absence from school and/or work due to clinical symptoms, depression and anxiety, specific treatment and need for hospitalization and/or ICU. The SF-36 is a generic instrument that consists of 36 questions in eight domains, which are pooled into two domains: physical and mental. The physical domain includes questions regarding the following items: physical function (10 questions related to routine activities), general health (five questions related to the patient's professional/educational life), pain (two questions) and physical aspects (four questions related to general well-being). The mental domain includes questions about mental health (five items), vitality (four items), social function (two items) and emotional well-being (three items). A question asking the patient to compare his/her current health to their health in the previous year is also included. Statistical Analysis: The data were evaluated with Microsoft Excel 2007, SPSS 17 and Statistica 7.0. Endpoints were considered statistically significant at p<0.05. The SF-36 internal reliability was tested using Cronbach's alpha with a range of zero to one, with zero indicating the absence of correlation between items and one indicating perfect correlation. A Cronbach's alpha value equal to or greater than 0.7 was considered acceptable.

RESULTS

Thirty-five patients were included in the study. The majority of patients were female (25 = 71.4%), from an urban area (85.7%) and had an average level of education (42.9%) and a medium-low socio-economic level (57.1%). The mean age was 40.7 years (DP±16.6 years). In 54% of the patients, the disease was well controlled, while 32% had mild symptoms and 14% had a moderate degree of symptoms. The SF-36 showed that 90.4% (mean) of patients had a score below 70 and 9.6% had scores equal to or higher than 70. The scores of the eight dimensions applied in all patients varied from 51.03 to 75.95; vitality and social aspects were more affected. The internal consistency of the evaluation was demonstrated by a Cronbach's alpha above 0.7 in seven of the eight domains (Table 1).
Table 1

Descriptive analysis of the SF-36 domains in 35 hereditary angioedema patients and Cronbach's alpha values.

NMinimumMaximumMeanMedianStandard deviationCronbach's alpha
Physical functioning3515.00100.0075.5785.0022.610.90
Lim. physical health350.0080.0060.5770.0022.020.94
Body pain350.00100.0058.1052.0030.150.90
General health perception3420.0090.0059.2640.0018.710.84
Vitality3415.0065.0051.0360.0012.420.78
Social functioning3525.0087.5054.2950.0013.870.66
Lim. emotional problems350.00100.0075.9583.3025.140.90
Mental health3425.0091.6765.2064.5816.850.86
There were no differences between the mean scores of the SF-36 in relation to gender, age, education level, or disease severity.

DISCUSSION

Although HAE is a rare disease, the patient burden is similar to other more common chronic diseases (6); the decrease in work productivity experienced by HAE patients is comparable with that experienced by patients with Crohn's disease or severe asthma. In addition, HAE patients must contend with the uncertainties of their disease. In our case, it should be considered that Brazil has yet to invest in the identification of these patients or access to therapy for the attacks. Danazol, the only medication supported by the Brazilian government, is classified as a high-cost drug. Patients taking androgens have reported more depressive symptoms and reduced productivity levels compared to patients not taking androgens (6). Androgens are often prescribed to patients with higher attack frequencies and more severe disease profiles (2). Only a few studies have evaluated quality of life (QOL) in HAE patients (6-8). In this study, Brazilian patients exhibited an impaired QOL, as measured by the SF-36, which is a generic questionnaire. The areas of their lives that were most affected were those related to vitality and social arenas. The patients felt tired, and their physical and emotional conditions impacted their social and professional activities. Poon et al. measured and compared Dermatology Life Quality Index (DLQI) scores in different dermatological conditions and included five patients with HAE (7). Bygum et al. addressed the improvement in the QOL of seven HAE patients related to medication used to ameliorate the edema (8). Most recently, Lumry et al. (6) evaluated the impact of HAE on QOL, applying one disease-specific survey and three standardized instruments; approximately 19% of the patients invited by the US HAE Association (n = 457) responded to the questionnaires. Patients with HAE reported decreased physical and mental health compared to a normal population (p<0.001) for all subscales and overall summary components. According to our data, the social effects of HAE had a larger impact on patient QOL than their physical condition. Several questionnaires have been developed to evaluate health-related quality of life. They provide information while evaluating or comparing the effects of clinical interventions or treatments, comparing differences between groups and evaluating the impact of side effects and potential problems demanding medical intervention. These questionnaires also help to decide resource allocation (9). The generic SF-36 questionnaire is important in the evaluation of quality of life in HAE patients; however, there is a need for studies using disease-specific surveys with specific instruments to serve as a point of comparison with generic questionnaires and evaluate the correlation with clinical severity (10). A specific HAE QOL questionnaire is currently being developed in Spain and will soon be translated and validated in other countries, including Brazil (11).

ACKNOWLEDGMENTS

We are thankful to Mrs Roberta Trefiglio and Mrs Sara Davis for revising the manuscript and its English version, respectively. This work has been partially supported by a grant from FIS (Fondo de Investigaciones Sanitarias, Grant number 060843). Dr. Teresa Caballero is an investigator from the IdiPAZ program for promoting research activities (2009).
  10 in total

1.  The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression.

Authors:  William R Lumry; Anthony J Castaldo; Margaret K Vernon; Marc B Blaustein; David A Wilson; Patrick T Horn
Journal:  Allergy Asthma Proc       Date:  2010 Sep-Oct       Impact factor: 2.587

2.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 3.  Critical review of generic and dermatology-specific health-related quality of life instruments.

Authors:  Hilde Both; Marie-Louise Essink-Bot; Jan Busschbach; Tamar Nijsten
Journal:  J Invest Dermatol       Date:  2007-11-08       Impact factor: 8.551

Review 4.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

5.  Quality of life research in pediatric oncology. Research methods and barriers.

Authors:  A S Bradlyn; A K Ritchey; C V Harris; I M Moore; R T O'Brien; S K Parsons; K Patterson; B H Pollock
Journal:  Cancer       Date:  1996-09-15       Impact factor: 6.860

6.  The extent and nature of disability in different urticarial conditions.

Authors:  E Poon; P T Seed; M W Greaves; A Kobza-Black
Journal:  Br J Dermatol       Date:  1999-04       Impact factor: 9.302

7.  2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema.

Authors:  Tom Bowen; Marco Cicardi; Henriette Farkas; Konrad Bork; Hilary J Longhurst; Bruce Zuraw; Emel Aygoeren-Pürsün; Timothy Craig; Karen Binkley; Jacques Hebert; Bruce Ritchie; Laurence Bouillet; Stephen Betschel; Della Cogar; John Dean; Ramachand Devaraj; Azza Hamed; Palinder Kamra; Paul K Keith; Gina Lacuesta; Eric Leith; Harriet Lyons; Sean Mace; Barbara Mako; Doris Neurath; Man-Chiu Poon; Georges-Etienne Rivard; Robert Schellenberg; Dereth Rowan; Anne Rowe; Donald Stark; Smeeksha Sur; Ellie Tsai; Richard Warrington; Susan Waserman; Rohan Ameratunga; Jonathan Bernstein; Janne Björkander; Kristylea Brosz; John Brosz; Anette Bygum; Teresa Caballero; Mike Frank; George Fust; George Harmat; Amin Kanani; Wolfhart Kreuz; Marcel Levi; Henry Li; Inmaculada Martinez-Saguer; Dumitru Moldovan; Istvan Nagy; Erik W Nielsen; Patrik Nordenfelt; Avner Reshef; Eva Rusicke; Sarah Smith-Foltz; Peter Späth; Lilian Varga; Zhi Yu Xiang
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

8.  Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits.

Authors:  Anette Bygum; Klaus Ejner Andersen; Carsten Sauer Mikkelsen
Journal:  Eur J Dermatol       Date:  2009 Mar-Apr       Impact factor: 3.328

Review 9.  Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema.

Authors:  Tom Bowen; Marco Cicardi; Konrad Bork; Bruce Zuraw; Mike Frank; Bruce Ritchie; Henriette Farkas; Lilian Varga; Lorenza C Zingale; Karen Binkley; Eric Wagner; Peggy Adomaitis; Kristylea Brosz; Jeanne Burnham; Richard Warrington; Chrystyna Kalicinsky; Sean Mace; Christine McCusker; Robert Schellenberg; Lucia Celeste; Jacques Hebert; Karen Valentine; Man-Chiu Poon; Bazir Serushago; Doris Neurath; William Yang; Gina Lacuesta; Andrew Issekutz; Azza Hamed; Palinder Kamra; John Dean; Amin Kanani; Donald Stark; Georges-Etienne Rivard; Eric Leith; Ellie Tsai; Susan Waserman; Paul K Keith; David Page; Silvia Marchesin; Hilary J Longhurst; Wolfhart Kreuz; Eva Rusicke; Inmaculada Martinez-Saguer; Emel Aygören-Pürsün; George Harmat; George Füst; Henry Li; Laurence Bouillet; Teresa Caballero; Dumitru Moldovan; Peter J Späth; Sara Smith-Foltz; Istvan Nagy; Erik W Nielsen; Christoph Bucher; Patrik Nordenfelt; Zhi Yu Xiang
Journal:  Ann Allergy Asthma Immunol       Date:  2008-01       Impact factor: 6.347

10.  Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project.

Authors:  Nieves Prior; Eduardo Remor; Carmen Gómez-Traseira; Concepción López-Serrano; Rosario Cabañas; Javier Contreras; Ángel Campos; Victoria Cardona; Stefan Cimbollek; Teresa González-Quevedo; Mar Guilarte; Dolores Hernández Fernández de Rojas; Carmen Marcos; María Rubio; Miguel Ángel Tejedor-Alonso; Teresa Caballero
Journal:  Health Qual Life Outcomes       Date:  2012-07-20       Impact factor: 3.186

  10 in total
  10 in total

Review 1.  The Humanistic, Societal, and Pharmaco-economic Burden of Angioedema.

Authors:  Hilary Longhurst; Anette Bygum
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

2.  Hereditary angioedema: health-related quality of life in Canadian patients as measured by the SF-36.

Authors:  Nina Lakhani Jindal; Elaine Harniman; Nieves Prior; Elia Perez-Fernandez; Teresa Caballero; Stephen Betschel
Journal:  Allergy Asthma Clin Immunol       Date:  2017-01-19       Impact factor: 3.406

Review 3.  Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema.

Authors:  Anette Bygum; Paula Busse; Teresa Caballero; Marcus Maurer
Journal:  Front Med (Lausanne)       Date:  2017-12-04

4.  Health-related quality of life and its risk factors in Chinese hereditary angioedema patients.

Authors:  Shuang Liu; Xue Wang; Yingyang Xu; Qun Xu; Yuxiang Zhi
Journal:  Orphanet J Rare Dis       Date:  2019-08-08       Impact factor: 4.123

5.  Psychometric study of the SF-36v2 in hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).

Authors:  Paola Palao-Ocharan; Nieves Prior; Elia Pérez-Fernández; Magdalena Caminoa; Teresa Caballero
Journal:  Orphanet J Rare Dis       Date:  2022-03-02       Impact factor: 4.123

6.  Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study.

Authors:  Anete S Grumach; Marina T Henriques; Maine L D Bardou; Daniele A Pontarolli; Jaco Botha; Mariangela Correa
Journal:  An Bras Dermatol       Date:  2022-05-30       Impact factor: 2.113

Review 7.  Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance.

Authors:  Huamin Henry Li
Journal:  Patient Prefer Adherence       Date:  2016-09-07       Impact factor: 2.711

8.  Expert perspectives on hereditary angioedema: Key areas for advancements in care across the patient journey.

Authors:  Aleena Banerji; Murat Baş; Jonathan A Bernstein; Isabelle Boccon-Gibod; Maria Bova; John Dempster; Anete Sevciovic Grumach; Markus Magerl; Kimberly Poarch; Manuel Branco Ferreira
Journal:  Allergy Rhinol (Providence)       Date:  2016-09-22

9.  Brazilian Guidelines for Hereditary Angioedema Management - 2017 Update Part 1: Definition, Classification and Diagnosis.

Authors:  Pedro Giavina-Bianchi; Luisa Karla Arruda; Marcelo V Aun; Regis A Campos; Herberto J Chong-Neto; Rosemeire N Constantino-Silva; Fátima R Fernandes; Maria F Ferraro; Mariana P L Ferriani; Alfeu T França; Gustavo Fusaro; Juliana F B Garcia; Shirley Komninakis; Luana S M Maia; Eli Mansour; Adriana S Moreno; Antonio A Motta; João B Pesquero; Nathalia Portilho; Nelson A Rosário; Faradiba S Serpa; Dirceu Solé; Priscila Takejima; Eliana Toledo; Solange O.R Valle; Camila L Veronez; Anete S Grumach
Journal:  Clinics (Sao Paulo)       Date:  2018-05-03       Impact factor: 2.365

10.  Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change.

Authors:  Kanokvalai Kulthanan; Leena Chularojanamontri; Chuda Rujitharanawong; Puncharas Weerasubpong; Marcus Maurer; Karsten Weller
Journal:  Health Qual Life Outcomes       Date:  2019-10-26       Impact factor: 3.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.